FDA Panel Supports Alnylam's Expanded Use of Gene Silencing Drug
TL;DR
The FDA's Cardiovascular and Renal Drugs Advisory Committee voted 9-3 in favor of Alnylam Pharmaceuticals' Onpattro for the treatment of ATTR cardiomyopathy, with panelists agreeing that the benefits outweigh the risks. While acknowledging the limited benefits, committee members expressed hope that clinicians would counsel patients on this treatment option.
Topics:businesshealthcare#advisory-committee#alnylam-pharmaceuticals#attr-cardiomyopathy#fda#healthcare#onpattro
- FDA adcomm votes in favor of Alnylam's new indication for Onpattro Endpoints News
- Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis Yahoo Finance
- FDA panel endorses Alnylam's heart drug — after picking apart its supporting data STAT
- Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease FiercePharma
- U.S. FDA panel backs expanded use of Alnylam's gene silencing drug Reuters
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News